[Interaction of sex steroids, prostaglandins (6-keto-PGF1 alpha, PGF2 alpha) and beta adrenergic agonists (adrenaline, fenoterol-Partusisten) in the human non-pregnant myometrium in vitro].
The in vitro effects of epinephrine and fenoterol (Partusisten) on contractility and prostaglandin (6-keto-PGF1 alpha, PGF2 alpha) production of human, non-pregnant myometrial strips dependent on the phase of the menstrual cycle and after pretreatment with estrogens and progesterone are reported. Superfusion of epinephrine (100 ng/ml) stimulated contractility and PG-synthesis of myometrial tissue from the proliferative phase of the cycle, whereas fenoterol (10 ng/ml) had only a little inhibitory effect. After pretreatment with conjugated estrogens (Presomen) the maximal epinephrine-stimulated contractions were correlated to a further increase in PGF2 alpha-synthesis even during fenoterol superfusion. In myometrial tissue obtained during the secretory phase of the cycle, both epinephrine and fenoterol had a significant inhibitory effect on spontaneous contractions associated with an increase in 6-keto-PGF1 alpha-production. After pretreatment with an estrogen-progestin combination (Primosiston) fenoterol superfusion resulted in a complete inhibition of myometrial contractions. These results demonstrate that estrogens increase the myometrial sensitivity to catecholamines leading to increased contractility and increased PGF2 alpha-synthesis, whereas progesterone probably mediates the beta-adrenergic inhibitory effect on myometrial contractions. Thus, the contractions inhibiting effect of the betamimetic drug fenoterol associated with decreased PGF2 alpha- und increased prostacyclin (PGI2) synthesis depends on the effect of progesterone in human, non-pregnant myometrium.
D015121:6-Ketoprostaglandin F1 alpha / Q000494:pharmacology*; D000328:Adult; D015237:Dinoprost; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004837:Epinephrine / Q000494:pharmacology*; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology*; D005260:Female; D005280:Fenoterol / Q000494:pharmacology*; D006801:Humans; D008597:Menstrual Cycle / Q000187:drug effects; D011460:Prostaglandins F / Q000494:pharmacology*; D014590:Uterine Contraction / Q000187:drug effects*
D004966:Estrogens, Conjugated (USP); D011460:Prostaglandins F; D005280:Fenoterol; D015121:6-Ketoprostaglandin F1 alpha; D015237:Dinoprost; D004837:Epinephrine
Wechselwirkung von Sexualsteroiden, Prostaglandinen (6-keto-PGF1 alpha, PGF2 alpha) und beta-adrenergen Agonisten (Adrenalin, Fenoterol-Partusisten) im menschlichen nicht-schwangeren Myometrium in vitro.